Clinical trials: Dementia, Senile
Alzheimer Disease
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab
This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US).
- Trial name
- NCT00916617
- Testing
- bapineuzumab
- Where
- 16 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pfizer
Alzheimer's Disease
Computer-Based Training for Mild Alzheimer's Disease
The primary objective of this study is to evaluate the effects of computer-based training program ("HiFi-AD") on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer's Disease (AD).
- Trial name
- NCT00319891
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Posit Science Corporation
Alzheimer Disease
Transcranial Alternating Current Stimulation Combined With 40Hz Sound Stimulation for Treatment Alzheimer's Disease
Alzheimer's disease is characterized by progressive cognitive decline, and cognition is associated with cerebral concussion. Previous studies have found reduced gamma energy in the brain of AD patients.
- Trial name
- NCT05251649
- Testing
- tACS combined with 40 Hz sound stimulation, Transcranial alternating current stimulation, 40 Hz sound stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Magnetic Resonance Imaging, Alzheimer's Disease
fMRI of Vulnerable Brain Regions in Persons at Risk for Alzheimer's Disease
The purpose of this study is to investigate the organization of memory and develop future methods for early detection of AD. Using functional magnetic resonance imaging (fMRI), we examine the responsiveness of the brain to memory…
- Conditions
- Magnetic Resonance Imaging, Alzheimer's Disease, Dementia, Adult Children
- Trial name
- ALZ (NCT00478491)
- Where
- United States
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimer's Disease (AD)
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).
- Trial name
- TOAD (NCT02593318)
- Testing
- Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Russell Swerdlow
Quality of Life (QOL), Anxiety
Testing the Efficacy of the "Syd" App on Improving Quality of Life and Mental Health Among University Students in the Kingdom of Saudi Arabia
The goal of this clinical trial is to learn if using the "See Yourself Differently" (syd) app can help improve quality of life and mental health for university students in Saudi Arabia.
- Conditions
- Quality of Life (QOL), Anxiety, Stress, Affect (Mental Function)
- Trial name
- NCT06979778
- Testing
- See Yourself Differently (syd) mobile app
- Where
- Saudi Arabia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- iamYiam Limited
Alzheimer Disease
An Integrated Intervention of Computerized Cognitive Training and Physical Exercise in Virtual Reality for People With Alzheimer's Disease (JDome)
JDOME is a randomized controlled trial to test the effectiveness of a computerized cognitive training with the Brainer web platform and aerobic training with the JDOME system vs.
- Trial name
- JDome (NCT05402423)
- Testing
- Computerized cognitive training plus aerobic exercise with the JDome System, Computerized cognitive training plus aerobic exercise with standard exercise bike
- Where
- Italy
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Alzheimer Disease
Neuro RX Gamma - Pivotal Phase
The active Neuro RX Gamma device uses non-invasive near-infrared energy delivered to the brain with the intention to improve cognitive functioning and quality of life in patients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT03484143
- Testing
- Active Neuro RX Gamma device
- Where
- 9 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- Vielight Inc.
Elderly, Alzheimer Disease
Orexin and Tau Pathology in Cognitively Normal Elderly
Alzheimer's disease (AD) is a common neurodegenerative disease characterized by the accumulation of amyloid plaques and neurofibrillary tangles.
- Trial name
- NCT03053908
- Testing
- Actigraphy, Nocturnal Polysomnograpahy (NPSG)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Alzheimer Disease, Dementia
Novel Neuroradiological Workflow for the Assisted DIAgnosis and Management of DEMentia with Artificial Intelligence
Identifying, screening and monitoring individuals at risk of Alzheimer's disease (AD) and dementia is a formidable challenge. Neuroimaging, and in particular magnetic resonance imaging (MRI), is crucial to detect structural…
- Trial name
- DIADEMA (NCT06877182)
- Testing
- Magnetic Resonance Imaging with Contrast
- Where
- Italy
- Volunteers
- 80,000 people
- Sponsor
- IRCCS SYNLAB SDN
Alzheimer Disease
Does EVOO Induce Gene and Metabolic Changes in Healthy Subjects
Investigators' recent findings from the pilot clinical trial in MCI individuals demonstrated EVOO improved vascular function and memory.
- Trial name
- NCT05929924
- Testing
- Extra virgin olive oil
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Augusta University
Alzheimer Dementia, Alzheimer Disease
Treating Hyperexcitability in AD With Levetiracetam
The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic…
- Conditions
- Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
- Trial name
- LeAD (NCT03875638)
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Alzheimer Disease
Fundus Camera Module for Early Detection of Alzheimer's Disease
Alzheimer's Disease (AD) affects tens of millions of people just in Europe. It is typically detected in its late stage when irreversible damage has already occurred, and current treatments are mostly conservative or palliative.
- Trial name
- NCT06841848
- Testing
- Fundoscopic Exam
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- I.R.C.C.S. Fondazione Santa Lucia
Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Digital Solutions for Predicting the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors
Population ageing is one of the main factors responsible for the global increase in the prevalence of dementia. Recent evidence suggests that modifiable risk factors, such as cardiovascular disease and lifestyle, may increase the…
- Trial name
- PrevAl (NCT07731191)
- Testing
- Digital solution for the prediction of the biological mechanisms of Alzheimer's disease through the analysis of risk factors
- Where
- 2 sites in Italy
- Volunteers
- 240 people
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Mild Cognitive Impairment, Probable Alzheimer's Disease
Dietary Treatments for Cognitive Impairment in Older Adults
This trial seeks to establish the feasibility of implementing a ketogenic, modified Atkins diet (MAD) to older adults with mild cognitive impairment (MCI) or early Alzheimer's disease (AD) living in the community.
- Trial name
- NCT02521818
- Testing
- Modified Atkins Diet, NIA Diet for Seniors
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Johns Hopkins University
Alzheimer's Disease
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
- Trial name
- NAVIGATE-AD (NCT02791191)
- Testing
- LY3202626
- Where
- 76 sites in United States, Australia and 2 more
- Volunteers
- 316 people
- Sponsor
- Eli Lilly and Company
Insomnia
SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid
The objective of this study is to compare the efficacy of a sleep intervention on improving cognitive function in older adults with symptoms of insomnia, determine the association between change in sleep measures and change in…
- Trial name
- NCT03954210
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Sleep and Lifestyle Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial
The main purpose of this study is to build upon the evidence captured in the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS; NCT02420756) trial to include valuable information regarding patient-reported outcomes and…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT2 (NCT02781220)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Utah
Mild Cognitive Impairment, Alzheimer Disease
Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Alzheimer's disease (AD) is the most common type of dementia, accounting for 50-75% of the estimated 47 million people with dementia worldwide.
- Trial name
- NCT03461276
- Testing
- ABvac40
- Where
- 23 sites in France, Italy and 2 more
- Volunteers
- 134 people
- Sponsor
- Araclon Biotech S.L.
Mild Cognitive Impairment, Dementia
Implications for Management of PET Amyloid Classification Technology
The main purpose of this study is to explore the impact of an amyloid positron emission tomography and computed tomography (PET/CT) scan on physician diagnosis and management, including drug management and care practices, for…
- Conditions
- Mild Cognitive Impairment, Dementia, Alzheimer's Disease
- Trial name
- IMPACT (NCT02778971)
- Testing
- [18F]Flutemetamol
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of Utah